HELIX - Precision Oncology Intelligence
Back to Portfolio
COMPUTATIONAL DEEP TECHPrecision Oncology

HELIX
Oncology Intelligence Platform

Making every oncologist as effective as the best oncologist. An AI-powered platform that transforms fragmented cancer care into a continuously-learning intelligence system spanning diagnostics, treatment matching, and clinical coordination.

20M
New Diagnoses/Year
$220B+
Global Oncology
<5%
Trial Enrollment
$35M
Series A Ask
$100B+
Target Market
5,000+
Active Trials
AI/ML
Core Technology
6
Licensed Patents
The Problem

Fragmented Cancer Care Kills

Cancer patients navigate a broken system where critical information falls through the cracks between specialists, diagnostics, and treatments.

The Information Gap

The average cancer patient sees 5-12 specialists who rarely communicate with each other. Critical treatment decisions are made with incomplete data. Patients retain only 20% of what's said during appointments while cognitively overwhelmed by their diagnosis.

Meanwhile, thousands of clinical trials run at any given time, yet fewer than 5% of eligible patients ever enroll. The gap isn't willingness - it's information and logistics.

The Billionaire vs. Everyone Else

GitLab CEO Sid Sijbrandij assembled a team of computational biologists, ran continuous diagnostics, and orchestrated personalized therapies for his cancer. HELIX productizes this approach for every oncologist and every patient.

Siloed Specialists5-12 doctors per patient with no shared intelligence layer; contradictions between recommendations go undetected
Multi-Omic Data ExplosionGenomic, transcriptomic, proteomic, liquid biopsy data exists but no integrated interpretation engine
Clinical Trial BlindnessFewer than 5% of eligible cancer patients enroll in trials - almost entirely an information failure
Reactive, Not ProactiveStandard oncology tests when something seems wrong; continuous monitoring catches recurrence months earlier
3D render of red blood cells flowing through bloodstream
The Solution

Oncology Intelligence, Phased

HELIX builds the intelligence layer that connects the entire cancer care journey - from diagnosis through treatment, one validated phase at a time.

Phase 1 - Core

Clinical Intelligence Layer

Ambient capture of every appointment, automatic structuring into a patient knowledge graph, AI-powered clinical trial matching against global registries, and care coordination summaries tailored per specialist domain. Ships in 6 months.

Phase 2 - Signal

Multi-Omic Diagnostic Fusion

Integration of genomic, transcriptomic, proteomic, liquid biopsy, bloodwork, and wearable data into a continuously-updated tumor model for 2-3 cancer types (breast, colorectal). Predictive alerts surface recurrence months before imaging.

Phase 3 - Predict

Treatment Response Engine

AI ranks treatment candidates by predicted efficacy for each patient's current tumor state. Drug repurposing engine matches 20,000+ approved drugs against multi-omic tumor profiles via ChEMBL, DrugBank, OncoKB, and DGIdb databases.

Phase 4 - Design

Personalized Therapy Coordination

Orchestration layer for personalized mRNA neoantigen vaccines, multi-target cell therapies, and AI-designed small molecules. Coordinates manufacturing logistics, regulatory pathways, and outcome tracking.

Red awareness ribbon symbolizing cancer awareness on gradient background
Market Opportunity

A $100B+ Addressable Market

Oncology is the single largest healthcare market on Earth, and precision medicine is reshaping it.

$220B+
Global Oncology Spend (2024)
$85B
Precision Oncology by 2030
32%
CAGR (AI in Oncology)
Precision Oncology Diagnostics$45B
Pharma Data Licensing (Outcomes)$15B
Oncology Data & Analytics$12B
Clinical Decision Support$8B
Clinical Trial Matching & Enrollment$3.2B
Vibrant neon-lit urban street in Tokyo representing global healthcare markets
Competitive Advantage

Why HELIX Wins

Full-Journey Intelligence

Tempus sells data to providers. Flatiron sells to pharma. Foundation Medicine does genomic profiling. HELIX is the first platform connecting diagnosis through treatment as continuous intelligence.

Physician-First Design

Built as decision support that makes oncologists heroes, not algorithm executors. Human-in-the-loop for every recommendation.

Data Flywheel

After 10,000 concentrated patients in 2-3 cancer types, prediction accuracy exceeds any individual oncologist's pattern recognition. This dataset is unreplicable.

UAE Beachhead Strategy

Launch in UAE with favorable regulatory environment, cash-pay patients, and government alignment with medical tourism innovation.

Federated Learning Architecture

Privacy-preserving model training across clinical sites without sharing raw patient data. Enables multi-institutional collaboration no competitor can replicate.

IP Protection

4-patent portfolio covering adaptive oncology knowledge graphs, multi-modal diagnostic fusion, genomic-aware trial matching, and federated oncology networks.

Grid of brain CT and MRI scans showing diagnostic imaging
Technology Roadmap

Path to Market

From clinical workflow tool to the world's most powerful oncology intelligence platform.

Phase 1 - Months 1-6

CORE: Clinical Intelligence

Ship ambient transcription + structured extraction + trial matching. Deploy at 3 UAE oncology centers. Validate physician adoption metrics. Secure 2-3 exclusive data partnerships.

Phase 2 - Months 6-18

SIGNAL: Diagnostic Fusion

Integrate liquid biopsy (ctDNA), whole genome + transcriptome sequencing, and proteomics into tumor model. Focus on breast and colorectal cancers. Expand to 10+ clinical sites.

Phase 3 - Months 18-36

PREDICT: Treatment Intelligence

Launch treatment response prediction and drug repurposing engine. FDA pre-submission for clinical decision support. Target 50+ clinical sites and 10,000 patient dataset.

Phase 4 - Months 36+

DESIGN: Therapy Orchestration

Coordinate personalized mRNA neoantigen vaccines and multi-target cell therapies. Full global platform expansion contingent on Phase 3 validation.

Advanced pharmaceutical manufacturing equipment in sterile facility
Use Cases

From Diagnosis to Survivorship

Community Oncology Augmentation

Community oncologists access the same intelligence as major cancer centers. Knowledge graph surfaces relevant clinical evidence and trials without manual research.

Multi-Disciplinary Tumor Board

AI generates comprehensive case summaries before tumor board review. Surfaces discordant recommendations and evidence gaps automatically.

Clinical Trial Enrollment

Continuous matching against 5,000+ active oncology trials. Logistics coordination handles pre-screening, site identification, and enrollment support.

Recurrence Monitoring

Post-treatment patients receive continuous multi-omic surveillance. Predictive alerts catch recurrence months before standard imaging intervals.

3D molecular structure with glass spheres representing drug compounds
Portfolio Synergies

Part of the Moonshot Rodeo Healthcare Suite

SYNAPSE Integration

Cancer patients on complex regimens receive drug interaction monitoring. Oncology care meets polypharmacy safety.

ORPHEON Cross-Platform

Rare cancer patients benefit from quantum drug repurposing. Overlapping patient populations across healthcare moonshots.

QCortex Backend

Shared AI/ML infrastructure and federated learning capabilities across portfolio. 80%+ resource utilization through workload pooling.